|
|
| | (±)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Basic information |
| Product Name: | (±)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | | Synonyms: | 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-;Bupivan;(R,S)-Bupivqacaine hydrochloride;rac-(2R*)-N-(2,6-Dimethylphenyl)-1-butyl-2β*-piperidinecarboxamide;(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;Ah 250;Bupivacaine Free Base;Bucain | | CAS: | 38396-39-3 | | MF: | C18H28N2O | | MW: | 288.43 | | EINECS: | 253-911-2 | | Product Categories: | | | Mol File: | 38396-39-3.mol |  |
| | (±)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical Properties |
| Melting point | 106-110℃ | | Boiling point | 423.4±45.0 °C(Predicted) | | density | 1.032±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:25.0(Max Conc. mg/mL);86.68(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);104.01(Max Conc. mM)
Ethanol:30.0(Max Conc. mg/mL);104.01(Max Conc. mM)
Ethanol:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.73(Max Conc. mM) | | form | Cyrstalline powder | | pka | 14.85±0.70(Predicted) | | Water Solubility | Soluble in water, ethanol, chloroform (slightly ), and acetone (slightly ). | | EPA Substance Registry System | 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- (38396-39-3) |
| | (±)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Usage And Synthesis |
| Description | Bupivacaine is a sodium channel blocker and local anesthetic. It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM. Bupivacaine (10 μM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively). It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 . Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals. | | Uses | Bupivacaine acts as a potent and long-acting local anesthetic agent in vivo. At 100 μM, it has been reported to inhibit the uptake of dopamine in striatal synaptosomes by 47%. | | Definition | ChEBI: A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. |
| | (±)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Preparation Products And Raw materials |
|